No Detail Found!

Letrozole role in breast cancer and infertility: a review of literature.

Author(s)
Faryal Javed Riphah International University, Lahore, Pakistan.
Summiya Zubair Riphah International University, Lahore, Pakistan.
Saba akram Lahore College of women university Lahore.
Misbah Sultana University College of Pharmacy, University of the Punjab, Lahore, Pakistan.
Saffia Sultana munir Shalamar Medical And Dental College Lahore
Ruqaiya Rasheed Kayani Clinical Pharmacist and Pharmacologist in Lahore, Pakistan.
Humayun Riaz Rashid Latif College of Pharmacy, Lahore, Pakistan
Rahat Shamim Punjab University College of Pharmacy, University of the Punjab, Lahore
Saeed Ur Rashid Nazir College of Pharmacy, University of Sargodha, Sargodha, Pakistan.
Muhammad Maaz Ali Beacon House College, University Road, Sargodha, Pakistan.
Abstract
Letrozole is being considered as potential prophylactic agent for breast cancer after discontinuation of 5-year tamoxifen therapy for steroid HR-positive breast cancer in postmenopausal women with breast cancer letrozole effect along with RT in aromatase expressing breast tumour cell showed efficacy as oral administration along with favourable toxicities when taken orally. Letrozole improves disease free survival in metastatic breast cancer Therapy with zoledonic acid is required as long-term use of aromatase inhibitior results in bone loss Letrozole is potent competitive aromatase inhibitor, a nonsteroidal Benzhydroltriazole derivative, highly selective. Women who had taken tamoxifen for 5 years after discontinuation have taken letrozole and chances of recurrence were less depending upon tumour characteristics. Therapy with letrozole lasts usually 3-4 months and has been extended up to 12 months. Aromatase inhibitors are now a days used worldwide as adjuvant therapy, particularly letrozole significantly improves disease free survival and time to distant recurrence In contrast to tamoxifen, letrozole cause decrease in circulating estrogen levels. Letrozole is better considered for disease free survival in postmenopausal women for preventing metastatic breast cancer in contrast to tamoxifen. Letrozole for its ovulatory effect is proved to be better with many respects as compared to clomiphene citrate. Though with some respects and in some research patterns clomiphene citrate came out to be a better ovulation stimulator but still letrozole has fewer side effects as compared to clomiphene citrate and more thickening of endometrial layer which is certainly a supportive factor for clinical pregnancy. Furthermore letrozole when used with combination of FSH and GnRH for ovulation stimulation, it decreases the dose required for fertility when either of both (FSH, GnRH) used alone. In women undergoing IUI and IVF it also plays a supportive role by improving the endocrine environment of the women.
Publication Details
Page(s) 66-74
Published Journal: journal of Peoples University of medical and Health Sciences, Pakistan., Volume: 12, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
Letrozole, Postmenopausal women, Aromatase inhibitors, Clomiphene, Tamoxifen., controlled ovarian hyperstimulation
0

Citations

0

Downloads

56

Views